Medical Device M&A Remains Active as Buyers Prioritize Quality Over Volume

While MedTech M&A activity has slowed from prior peaks, buyers remain active for the right opportunities.

In an interview with Medical Design Briefs, Bryan Hughes, Managing Director at PMCF Investment Banking, shared his perspective on the current state of the healthcare and medical device M&A market and the factors influencing buyer behavior.

According to Hughes, “buyers have become far more selective and disciplined, reflecting a lower-volume, higher-conviction market where capital is being concentrated behind a smaller number of clearly essential, clinically validated assets rather than spread across breadth.”

That selectivity does not mean a lack of interest. Rather, buyers are spending more time evaluating targets and focusing their attention on businesses with characteristics they believe will hold up over time.

Quality Remains the Defining Theme in MedTech M&A

Companies with recurring revenue, strong competitive positions, established customer relationships, and products that play an important role in patient care continue to attract interest from both strategic and financial buyers.

As Hughes noted, “High-conviction assets are clinically essential with recurring or consumable revenue, a defensible market position, a clean regulatory and reimbursement profile, and resilient margins.”

For sellers, the implication is straightforward: buyers want to understand what drives demand, how sustainable that demand is, and whether the business can maintain performance through different market environments.

That is particularly relevant across medical devices, healthcare services, diagnostics, contract manufacturing, and consumables, where a company’s market position and customer value proposition often play a significant role in buyer interest.

Strategic Buyers Continue to Lead Activity

Strategic acquirers remain an important source of activity across the healthcare and medical technology sectors, accounting for roughly 87 percent of Q1 activity according to PMCF’s proprietary data.

“For founder-led and middle-market companies, it means leading the story with strategic fit and synergy potential, expecting strategics to be the primary buyer pool, and preparing for rigorous, capability-focused diligence rather than a purely financial process,” Hughes said.

Many strategic buyers have the resources to pursue acquisitions that fill product gaps, broaden capabilities, expand customer access, or strengthen existing platforms. As a result, companies considering a sale process should be prepared to explain not only their financial performance but also how they fit into a potential buyer’s broader objectives.

Growth alone is rarely enough, as buyers are looking for growth they can understand, validate, and support through diligence.

Outlook for MedTech and Healthcare M&A

The market remains influenced by financing costs, policy uncertainty, and broader economic conditions. Even so, buyers continue to show interest in businesses tied to recurring demand and essential healthcare products and services.

“We see the strongest renewed momentum where recurring demand meets scarcity: diagnostics, consumables and disposables, and outsourced manufacturing and services, and expect a gradual recovery as rates ease and significant pent-up sponsor capital re-engages,” Hughes said.

For owners considering a sale, recapitalization, or strategic partnership, preparation remains important. Companies that can clearly communicate their market position, growth drivers, and operational strengths are often better equipped to engage prospective buyers and navigate a transaction process.

Read the full interview with Bryan Hughes in Medical Design Briefs:
MedTech M&A’s Flight to Quality: Why Buyers Are Making Fewer, Bigger Bets

Learn more about PMCF’s Healthcare & MedTech investment banking practice:
PMCF Healthcare & MedTech